When is it appropriate and/or necessary to utilize mRNA testing in the diagnosis and staging of HL?

FAQ published on June 1, 2016
Download Transcript Download Audio
Andrew Evens, DO, MSc, FACP
Professor and Chief, Division of Hematology/Oncology
Tufts University School of Medicine
Director, Tufts Cancer Center
Tufts Medical Center
Boston, Massachusetts
When is it appropriate and/or necessary to utilize mRNA testing in the diagnosis and staging of HL?

Managing Hodgkin Lymphoma recently talked with Dr. Andrew Evens of the Tufts University School of Medicine about using mRNA testing in the diagnosis and staging of Hodgkin lymphoma. [Editor’s note: Dr. Evens’ transcript has been edited to improve readability]

I’m often asked when is it appropriate and/or necessary to utilize mRNA testing to diagnosis and stage Hodgkin lymphoma. The relatively quick answer, at least in current clinical practice, is never. In another words, frankly, micro RNA or mRNA or, for that matter, any genetic testing at this point in Hodgkin lymphoma, still remains experimental and research-based. There is definitely exciting and burgeoning data that is looking at genomics, proteomics, and even metabolomics in Hodgkin lymphoma, as well as in other cancers, utilizing these strategies as potential biomarkers to help us understand prognosis. These could even help us find a really robust predictive tool that could help us manage our patients. Right now, however, these strategies are still in the experimental and research phase in terms of managing patients, although I do hope this will be integrated into clinical practice, if not in the next year, then in the next couple of years.

Thank you for viewing this activity.

For further information about this important subject, please refer to the related resources and activities on the Managing Hodgkin Lymphoma website, as identified below.

Last modified: May 3, 2016
Related Items by Author
What are the roles of immunohistochemistry studies versus flow cytometry results in diagnosing HL?
Andrew Evens, DO, MSc, FACP
FAQ published on August 4, 2016
Which factors are more important when developing treatment plans for the newly diagnosed HL patient?
Andrew Evens, DO, MSc, FACP
FAQ published on May 4, 2016
What are the appropriate treatments for the elderly patient with Hodgkin lymphoma?
Andrew Evens, DO, MSc, FACP
FAQ published on February 12, 2014

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2018 MediCom Worldwide, Inc. All rights reserved